

BRUSSELS | 20-22 MARCH 2018

18TH GENERAL MEMBERSHIP MEETING OF THE REPRODUCTIVE HEALTH SUPPLIES COALITION


Beginning with the End in Mind: Multiple Meanings for Contraceptive Research & Development

Kate Rademacher, Technical Advisor, FHI 360






Begin with the end in mind in order to achieve...



Strategy #1: Conduct acceptability research at all phases of development and introduction



A conceptual framework



Callahan R, et al. 2017

Strategy 2: Reflect service delivery contexts when designing and developing new products







Condoms by Drone, NPR

Strategy 3: Include actionable, binding terms in contractual agreements





Strategy 4: At <u>all</u> stages, work to keep Cost of Goods Sold as low as possible







Strategy 5: Be flexible & embrace change







Contraceptive Technology Innovation at FHI 360

Expanding Access to Underutilized Contraceptive Methods





- Manufactured by Shanghai Dahua Pharmaceutical
- "Levoplant" is global trade name for product with new levonorgestrel supplier; currently being re-registered
- DKT International is new global marketing partner.
- WHO Prequalified for 3 years of use






Contraceptive Implant Prices 2009-2013:

2012



Changes Since Global Introduction of Sino-implant (II)




volume guarantees


savings

Levonorgestrel Intrauterine System (LNG-IUS): Access to Method Remains Limited





Global learning agenda developed in 2016



- ✓ First approved for use in 1990, the LNG-IUS has a nearly 30-year researchto-practice gap in FP 2020 countries
- ✓ Landscape may be changing as more affordable products become available



Contraceptive Technology Innovation at FHI 360

New Methods Under Development



Development of a 6-month injectable

Currently, no injectable is labeled more than 3 months

 Discontinuation rates are high, in part due to late or missed re-injection visits

A longer-acting injectable would likely:

- Improve re-injection compliance
- Reduce time & travel costs for clients
- Reduce burden on health system

FHI 360 and collaborators are currently evaluating multiple formulations



Target Product Profile for a Longer-acting Injectable

Development of a Biodegradable Implant

Currently, implants require removal by a skilled provider

A biodegradable implant would address current problems including:

- Lack of trained personnel
- Inability among women to access or afford the procedure
- Burden on health system
- In addition, product with "intermediate" duration of efficacy would fill method mix gap

FHI 360 and collaborators are evaluating multiple designs/formulations




Adapting microneedle patches for contraception


Targeting contraceptive steroid hormones to the dermal versus subcutaneous space



Microneedle patch is applied to skin



Microneedles dissolve and release the contraceptive





Sharps-free backing is removed and discarded


Polymer Microneedles















Adapted from Micron Biomedical and Mark Prausnitz

Microneedles Acceptability Research

Goal: Incorporate end user feedback into product design decisions

Study objectives:

- Explore initial acceptability of the microneedle patch for contraceptive delivery and potential barriers to use;
- Define desired qualities or characteristics of a microneedle patch for contraceptive use;
- Quantify relative importance of various contraceptive microneedle patch attributes

Study sites: New Delhi, India and Ibadan, Nigeria









Contraceptive Technology Innovation

Global Knowledge Sharing



CTI Exchange



CALLIOPE

kah-LY-ah-pee

Contraceptive Pipeline Database

Calliope, the Contraceptive Pipeline

Database, includes information on potential
contraceptive targets and leads, products in
development, and a selection of products
only available in limited markets.



CAPRI, the Contraceptive Active
Pharmaceutical Ingredient Database, lists
biological and chemical properties for 27
active pharmaceutical ingredients found in
contraceptives, along with data on their
pharmacology, toxicology, impurities,
metabolites, and use in marketed products.

www.ctiexchange.org



